A reoccurring theme here is that scientific RCT's seem incapable of establishing weather the cells are of benefit or not, and only seem capable of examining the primary end point that is selected. The failure reasons have nothing to do with the efficacy of the treatment and 100% to do with the selection of the primary end point.
As the FDA says - if the primary end point is not met then all secondary end points cannot be considered. That is the scientific method?
Maybe they should change the primary end point to - 'treatment improves patients health'.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-113
-
- There are more pages in this discussion • 311 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |